Mind Medicine Inc. (MNMD), which recently successfully completed a phase IIb trial of its lead drug candidate, MM-120 ODT, in Generalized Anxiety Disorder, is on track to advance the compound into a late-stage trial this quarter.
MM-120 ODT is a pharmacologically optimized form of Lysergide D-tartrate (LSD) being developed for generalized anxiety disorder and other brain-based disorders. LSD was first synthesized in 1938, and its psychoactive properties were discovered in 1943.
For comments and feedback contact: editorial@rttnews.com
June 19, 2026 16:46 ET Major central banks continued to dominate the economic news flow this week too, led by the Federal Reserve, as they announced their latest policy decisions. The Federal Reserve policy session was in focus as it was the first to be led by the new chief Kevin Warsh. In Europe, central banks of the U.K. and Switzerland announced their rate decisions. In Asia, the Bank of Japan drew attention for its policy moves, while data out of China threw some light on the state of the economy.